피하 피임 임플란트 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Subdermal Contraceptive Implants Market size is expected to reach USD 2.00 Billion in 2034 from USD 0.99 Billion (2025) growing at a CAGR of 8.14% during 2026-2034.

The subdermal contraceptive implants market is poised for significant growth, driven by the increasing demand for long-acting reversible contraceptive (LARC) methods among women seeking effective family planning solutions. As awareness of reproductive health and the importance of contraceptive options rises, the adoption of subdermal implants is surging. These implants offer a convenient and discreet method of contraception, providing protection against pregnancy for several years with minimal maintenance. Innovations in implant design and formulation are enhancing the safety and efficacy of these devices, making them more appealing to healthcare providers and patients alike.

Moreover, the growing emphasis on women's health and empowerment is influencing the subdermal contraceptive implants market. As more women seek control over their reproductive choices, the demand for accessible and effective contraceptive options is increasing. The integration of educational initiatives and outreach programs is also contributing to the growth of this market, as healthcare providers work to inform women about the benefits and availability of subdermal implants.

Furthermore, the increasing focus on research and development in contraceptive technologies is fostering innovation in the subdermal contraceptive implants market. Collaborations between pharmaceutical companies, healthcare providers, and research organizations are driving advancements in implant technology, leading to the development of next-generation products that address current limitations and improve patient care.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Etonogestrel Implant
• Levonorgestrel Implant

By Distribution Channel

• Hospital
• Gynecology Clinics
• Community Health Care Centres
• Others

COMPANIES PROFILED

• Merck Co, Inc, Shanghai Dahua Pharmaceutical Co, Ltd, Bayer AG, Baxter, BD, Gerresheimer AG, Pfizer, Inc, Novartis AG, SCHOTT, Eli Lilly and Company, Sandoz Group AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd, West Pharmaceutical Services, Inc, SHL Medical AG, Insulet Corporation

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Etonogestrel Implant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Levonorgestrel Implant Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Gynecology Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Community Health Care Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SUBDERMAL CONTRACEPTIVE IMPLANTS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Merck & Co.Inc
  • 8.2.2 Shanghai Dahua Pharmaceutical Co., Ltd
  • 8.2.3 Bayer AG
  • 8.2.4 Baxter
  • 8.2.5 BD
  • 8.2.6 Gerresheimer AG
  • 8.2.7 PfizerInc
  • 8.2.8 Novartis AG
  • 8.2.9 SCHOTT
  • 8.2.10 Eli Lilly And Company
  • 8.2.11 Sandoz Group AG
  • 8.2.12 Terumo Corporation
  • 8.2.13 Teva Pharmaceutical Industries Ltd
  • 8.2.14 West Pharmaceutical ServicesInc
  • 8.2.15 SHL Medical AG
  • 8.2.16 Insulet Corporation